Contract 36C25522N0210
New York Blood Center, Inc. · Department Of Veterans Affairs · March 31, 2022
New York Blood Center, Inc. was awarded a federal contract by Department Of Veterans Affairs on March 31, 2022 for $668,000 of work in biological product (except diagnostic) manufacturing. Performance is in Kansas City, MO. This is a task or delivery order issued under parent IDIQ 36C25522D0022. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on January 29, 2024.
Contract details
- PIID
- 36C25522N0210
- Parent IDIQ
- 36C25522D0022
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325414 · Biological Product (Except Diagnostic) Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Kansas City, MO
- First action
- March 31, 2022
- Latest action
- January 29, 2024
Description
BLOOD, BLOOD PRODUCTS AND RELATED SERVICES
Modification timeline
-
January 29, 2024Mod P00002$-115.3K
-
May 17, 2023Mod P00001$30.6K
-
March 31, 2022Base award$752.8K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| American National Red Cross, The | Department Of Veterans Affairs | March 25, 2026 | $1.65M |
| New York Blood Center, Inc. | Department Of Veterans Affairs | March 18, 2026 | $670.0K |
| Binding Site, Inc., The | Department Of Veterans Affairs | March 18, 2026 | $137.6K |
| Binding Site, Inc., The | Department Of Veterans Affairs | March 18, 2026 | $102.8K |
| Binding Site, Inc., The | Department Of Veterans Affairs | March 18, 2026 | $124.6K |
| Binding Site, Inc., The | Department Of Veterans Affairs | March 18, 2026 | $0 |
Top contractors in NAICS 325414
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Pfizer Inc | 3 | $15.27B |
| 2 | Sanofi Vaccines Us Inc. | 606 | $9.38B |
| 3 | Regeneron Pharmaceuticals Inc | 1 | $5.57B |
| 4 | Merck Sharp & Dohme Corp. | 56 | $3.99B |
| 5 | Emergent Biodefense Operations Lansing Llc | 16 | $3.34B |
| 6 | Merck Sharp & Dohme Llc | 15 | $3.33B |
| 7 | Pfizer Inc. | 25 | $3.11B |
| 8 | Glaxosmithkline Holdings (Americas) Inc. | 109 | $2.24B |
| 9 | Modernatx, Inc. | 1 | $1.75B |
| 10 | Bavarian Nordic A/S | 1 | $1.01B |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36C25522N0210?
Contract 36C25522N0210 is a federal contract awarded to New York Blood Center, Inc. by Department Of Veterans Affairs on March 31, 2022 for $668,000 of work classified under BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING. It has been modified 2 times since the base award.
Who won contract 36C25522N0210?
New York Blood Center, Inc. won contract 36C25522N0210 from Department Of Veterans Affairs.
How much is contract 36C25522N0210 worth?
Contract 36C25522N0210 has obligated $668,000 to date, with a total potential value of $783,000 if all options are exercised.